Preclinical and human studies suggest that hippocampal dysfunction is a key factor in the onset of psychosis. People at Clinical High Risk for psychosis (CHR-P) present with a clinical syndrome that can include social withdrawal and have a 20-35% risk of developing psychosis in the next 2 years. Recent research shows that resting hippocampal blood flow is altered in CHR-P individuals and predicts adverse clinical outcomes, such as non-remission/transition to frank psychosis. Previous work in healthy males indicates that a single dose of intranasal oxytocin has positive effects on social function and marked effects on resting hippocampal blood flow. The present study examined the effects of intranasal oxytocin on hippocampal blood flow in CHR-P individuals. In a double-blind, placebo-controlled, crossover design, 30 CHR-P males were studied using pseudo-continuous Arterial Spin Labelling on 2 occasions, once after 40IU intranasal oxytocin and once after placebo. The effects of oxytocin on left hippocampal blood flow were examined in a region-of-interest analysis of data acquired at 22-28 and at 30-36 minutes post-intranasal administration. Relative to placebo, administration of oxytocin was associated with increased hippocampal blood flow at both time points (p = .0056; p = .034), although the effect at the second did not survive adjustment for the effect of global blood flow. These data indicate that oxytocin can modulate hippocampal function in CHR-P individuals and therefore merits further investigation as a candidate novel treatment for this group.

中文翻译：

---

催产素调节临床精神病高危人群的海马灌注。

临床前和人体研究表明，海马体功能障碍是精神病发作的关键因素。处于精神病临床高风险 (CHR-P) 的人会出现临床综合征，其中可能包括社交退缩，并且在未来 2 年内有 20-35% 的风险患上精神病。最近的研究表明，CHR-P 个体的静息海马血流发生改变，并预测不良临床结果，例如未缓解/过渡到明显的精神病。之前对健康男性的研究表明，单剂量的鼻内催产素对社会功能有积极影响，并对静息海马体血流有显着影响。本研究检查了鼻内催产素对 CHR-P 个体海马血流的影响。在双盲、安慰剂对照、交叉设计中，对 30 名 CHR-P 男性进行了 2 次伪连续动脉自旋标记研究，一次是在 40IU 鼻内催产素后，另一次是在安慰剂后。在鼻内给药后 22-28 分钟和 30-36 分钟获得的数据的感兴趣区域分析中检查催产素对左海马血流的影响。相对于安慰剂，催产素的给药在两个时间点都与海马血流量增加有关（p = .0056；p = .034），尽管第二个时间点的效果在调整整体血流量的影响后无法幸免。这些数据表明催产素可以调节 CHR-P 个体的海马功能，因此值得进一步研究作为该组的候选新疗法。40IU 鼻内催产素后一次，安慰剂后一次。在鼻内给药后 22-28 分钟和 30-36 分钟获得的数据的感兴趣区域分析中检查催产素对左海马血流的影响。相对于安慰剂，催产素的给药在两个时间点都与海马血流量增加有关（p = .0056；p = .034），尽管第二个时间点的效果在调整整体血流量的影响后无法幸免。这些数据表明催产素可以调节 CHR-P 个体的海马功能，因此值得进一步研究作为该组的候选新疗法。40IU 鼻内催产素后一次，安慰剂后一次。在鼻内给药后 22-28 分钟和 30-36 分钟获得的数据的感兴趣区域分析中检查催产素对左海马血流的影响。相对于安慰剂，催产素的给药在两个时间点都与海马血流量增加有关（p = .0056；p = .034），尽管第二个时间点的效果在调整整体血流量的影响后无法幸免。这些数据表明催产素可以调节 CHR-P 个体的海马功能，因此值得进一步研究作为该组的候选新疗法。相对于安慰剂，催产素的给药在两个时间点都与海马血流量增加有关（p = .0056；p = .034），尽管第二个时间点的效果在调整整体血流量的影响后无法幸免。这些数据表明催产素可以调节 CHR-P 个体的海马功能，因此值得进一步研究作为该组的候选新疗法。相对于安慰剂，催产素的给药在两个时间点都与海马血流量增加有关（p = .0056；p = .034），尽管第二个时间点的效果在调整整体血流量的影响后无法幸免。这些数据表明催产素可以调节 CHR-P 个体的海马功能，因此值得进一步研究作为该组的候选新疗法。